Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ATHENA’s First Launch in Russia with Levocetirizine ODT
Details : Levocetirizine ODT is second-generation piperazine derivative with potent H1-selective antihistaminic activity,n Improved oral bioavailability and onset of action vs. conventional oral slide form by avoiding hepatic first-pass effect.
Product Name : Levocetirizine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2020
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable